Stem cell therapy for rheumatoid arthritis

barbara

Pioneer Founding member
Medical News Today
https://www.medicalnewstoday.com/articles/325583.php
27 June 2019 By Charlotte Lillis Reviewed by Brenda B. Spriggs, M.D. FACP

Rheumatoid arthritis is an autoimmune condition that mainly affects the joints. Stem cell therapy is a relatively new area of research that is showing promise in treating autoimmune conditions such as this.

In rheumatoid arthritis (RA), the immune system mistakenly attacks the tissue that lines the joints, which can cause pain, inflammation, swelling, and stiffness.

This inflammation can extend to the cartilage that covers the ends of joints and cause irreversible damage and loss of function. It can also damage other tissues, including the lungs, heart, kidney, skin, and eyes.

Stem cell therapy may help reduce inflammation and increase the presence of healthy cells in the body. This article outlines the current knowledge on stem cell therapy as a possible treatment for RA.

What is stem cell therapy?

A stem cell is a type of cell not specialized to perform a specific role. Instead, it has the unique ability to develop into one of many different types of cell.

Stem cell therapy uses stem cells to replace dead and diseased cells within the body.

The human body contains over 200 different types of cell. Usually, each type has certain characteristics that allow it to perform a specific role.


Cells with similar roles group together to form tissues, which then organize to form the body's organs. For example, the heart is a collection of muscle tissues.

Scientists source the stem cells from body tissue, either from an embryo or an adult human, and isolate them in the laboratory. After manipulating the cells to develop into specific types, they then inject the cells into the recipient's blood or tissue.

How can it help treat RA?
Researchers are investigating ways of using stem cells to control inflammation and regenerate damaged tissues.

RA causes inflammation in the tissues between joints. This results in a loss of cartilage, which is the connective tissue that cushions the joints. Over time, cartilage loss can damage the joint and nearby bone.

Mesenchymal stem cells (MSCs) are types of stem cell that can develop into cartilage and bone. Synovial MSC therapy involves injecting these cells directly into the tissues surrounding the affected joints.

Some research shows that MSCs are also able to suppress the immune system and reduce the body's inflammatory response. This makes MSC therapy a promising treatment option for autoimmune conditions such as RA.

Although some clinics use stem cell therapy to treat arthritis, it is not standard practice and may have some serious side effects. Stem cell research is still in the very early stages of scientific investigation and needs more analysis.

What the research says
A researcher looking through a microscope
Research is ongoing about whether stem cell therapy is an effective treatment for RA.
One 2013 study investigated the efficacy of MSC therapy for people with RA.

All 172 participants continued to take their regular RA medication during the course of the study. A subset of the participants also received two MSC treatments via intravenous injection, while another subset received placebo injections (the controls).

Compared with the controls, those who received the MSC treatment showed a significant remission of the condition. The team measured the extent of remission using the improvement criteria of the American College of Rheumatology, the 28-joint disease activity score, and the Health Assessment Questionnaire.

Improvements also correlated with increased levels of regulatory T cells (RTCs) in the blood. RTCs stop the immune system from attacking the body's own cells. As such, they play a vital role in controlling inflammation.

One 2015 study reported similar effects of MSCs on the immune cells of mice with RA.

Its authors explain that MSC treatment increased RCT levels while lowering levels of cells that promote inflammation.

The Food and Drug Administration (FDA) state that clinical trials of MSC therapy for inflammatory conditions have not produced consistent results.

Until recently, researchers sourced human MSCs (hMSCs) from a range of tissues and donors. These different cell batches can vary greatly in their ability to suppress the immune system.

In 2017, scientists began developing reliable methods for predicting the efficacy of different batches of hMSCs. Conducting further research using these methods may help scientists determine whether stem cell therapy can help treat RA.

FDA regulation
Currently, the FDA only approve the use of umbilical hematopoietic stem cells (uHSCs).

These cells derive from umbilical cords and can develop into different types of blood cell. People mainly receive uHSCs to help treat blood disorders.

The FDA do not regulate the use of other types of stem cell, such as MSCs. However, they may approve and oversee clinical trials that use such cells.

Clinical trials take place under an FDA-permitted Investigational New Drug Application, which indicates that the trial meets their safety standards.
 
Top